$SYRE SEC Filings

Introductory. Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 4,117,648 shares (the “Firm Shares”) of its c...

Received 28,933 shares by exercise or conversion ($420K) · Sold 28,933 shares ($2.63M)

Sold 15,000 shares ($1.38M)

Received 17,500 shares by exercise or conversion ($254K) · Sold 17,500 shares ($1.57M) · Received 7,500 shares by exercise or conversion ($109K) · 1 more

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

Received 27,999 shares by exercise or conversion ($406K) · Sold 27,999 shares ($2.44M) · Received 400 shares by exercise or conversion ($5.8K) · 1 more

Received 7,500 shares by exercise or conversion ($109K) · Sold 7,500 shares ($655K) · Sold 18,232 shares ($1.63M)

Sold 15,000 shares ($1.31M)

Received 5,000 shares by exercise or conversion ($52K) · Sold 23,000 shares ($2.4M)